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To the Editor, 65 
 66 
Thirty to 50% of preschool children experience asthma-like symptoms, such as wheezing,1–3 67 
but only approximately 30% of these children will develop asthma. Due to the non-specific 68 
symptoms of asthma at preschool age and the lack of a diagnostic test for asthma in this age 69 
group, it is difficult to determine which child will develop asthma. Several prediction models 70 
based on family, personal and environmental factors have been developed to improve the 71 
early diagnosis of asthma,2,3 yet these are of modest clinical value.4 In addition, these models 72 
are based on children with respiratory symptoms, while asthma prediction at a time point 73 
when no clinical symptoms have occurred may identify children at risk for asthma to start 74 
early preventative measures.  75 
 76 
It has been proposed that genetics may improve asthma prediction.4 Recently, two consortia 77 
published the results on large meta-analyses of genome wide association studies (GWAS), 78 
which doubled the number of genetic variants that are associated with asthma.5,6 The Trans-79 
National Asthma Genetic Consortium (TAGC) consortium described 18 loci to be associated 80 
with asthma in a multi-ancestry meta-analysis in 142,000 subjects,5 with 5 additional loci 81 
specifically related to pediatric asthma. Moreover, the SHARE consortium discovered 136 82 
independent genetic variants to be associated with allergic disease (asthma, hay fever or 83 
eczema) in 360,000 subjects, with almost all variants contributing to either disease.6 These 84 
asthma associated variants from TAGC and SHARE offer the opportunity to investigate 85 
asthma prediction based on genetic risk scores.  86 
We generated a prediction model for asthma in the first 8 years of life based on the 87 
combination of family, perinatal, environmental and genetic risk factors, with the aim to 88 
investigate the added value of genetics at predicting childhood asthma determined by easy 89 
available factors known in the first year of life. Asthma definition was based on asthma ever 90 
from age 3 till age 8 years, in which cases had one or more of the following three criteria; (1) 91 















(dyspnea) in the last 12 months, or (3) prescription of inhalation steroids for respiratory or 93 
lung problems prescribed by a doctor in last 12 months. 94 
We used data from the Prevalence and Incidence of Asthma and Mite Allergy birth cohort 95 
(PIAMA)7 with inclusion of 1,968 children (see Online Repository). With univariate and 96 
multivariate logistic regression analysis, familial, perinatal and environmental risk scores 97 
were made based on variables which previously predicted asthma in children experiencing 98 
respiratory symptoms.2 We selected independent single nucleotide polymorphisms (SNPs) 99 
and calculated weighted genetic risk score (GRS) based on the TAGC and SHARE data (see 100 
Online Repository).5,6 Receiver-operating characteristics (ROC) analysis was performed to 101 
test the added value of the GRSs to the familial, perinatal and environmental scores. Since 102 
the predictors of the non-genetic risk scores were generated from PIAMA data we tested for 103 
optimism caused by overfitting with the use of an internal bootstrap validation approach 104 
(using the R package ‘rms’). The predicted probabilities of the separate risk scores were 105 
categorized into deciles to analyze the discriminative performance of each score. Replication 106 
of the models obtained in PIAMA was performed in BAMSE (Children/Barn, Allergy, Milieu, 107 
Stockholm, Epidemiology) (n=427), a Swedish birth cohort, with a comparable design to 108 
PIAMA.8  109 
 110 
Of the 1,968 children with genotype data in our study, 1,858 children had information on the 111 
presence of asthma in the first 8 years of life. Of these, 42.6% (n=792) had asthma ever in 112 
the first 8 years of life (Table I). 113 
The combined familial, perinatal and environmental risk score included parental allergy (OR 114 
(95% CI)=1.38 (1.08-1.76), parents allergic to pets (1.43 (1.10-1.85), parental inhaled 115 
medication (1.54 (1.17-2.04), siblings with asthma (2.46 (1.52-3.99), low parental education 116 
(1.33 (1.07-1.65), male gender (1.44 (1.20-1.74), breastfeeding <16 weeks (1.32 (1.09-1.60), 117 
low birth weight <2500g (2.15 (1.24-3.70), pets at home during pregnancy (1.21 (1.00-1.46), 118 
smoking mother during pregnancy (1.45 (1.13-1.88), and older siblings living at home (1.20 119 















environmental and genetic risk score indicated that the familial risk score had the strongest 121 
prediction (PIAMA; OR=1.25, P =3.17x10-19, BAMSE; OR=1.46, P =3.17x10-13) (Table E2). 122 
The combined model of familial, perinatal and environmental factors showed moderate 123 
discrimination (area under receiver operating characteristic curve (AUC)=0.65), with similar 124 
predictive properties of this model in the BAMSE study (AUC=0.67). Optimism corrected 125 
AUC in PIAMA was 0.65 which indicates no overfitting of data. In PIAMA , including the 126 
TAGC GRS in the models with the familial, perinatal and environmental risk score showed an 127 
AUC of 0.66, whereas the inclusion of the SHARE GRS had an AUC of 0.65 (Fig 1A-B). 128 
There was no improvement over the risk prediction based on familial, perinatal and 129 
environmental factors (AUC difference between familial, perinatal and environmental factors 130 
solely and combined with GRS: TAGC;  Z=-0.55, P=0.29, SHARE; Z-0.0, P=0.5) Replication 131 
analyses in BAMSE showed similar results with AUC of 0.69 (AUC difference between 132 
familial, perinatal and environmental factors solely and combined with GRS: TAGC;  Z=-0.55, 133 
P=0.29, SHARE; Z-0.83, P=0.2) (Fig 1C-D). Discriminative analysis showed best predictive 134 
probability for the familial risk score (Fig E1A-B, E2A-B). In PIAMA the results did not change 135 
when we used a more specific asthma diagnosis as the outcome, doctor’s diagnosed asthma 136 
at age 8, which will exclude the transient wheezers (model of familial, perinatal and 137 
environmental factors (AUC=0.64) combined with TAGC GRS: AUC=0.64; SHARE GRS: 138 
AUC=0.64). It has been suggested that genetic risk prediction may improve when adding 139 
additional SNPs that are associated with the disease, albeit not at genome wide significance 140 
threshold. To investigate this possibility, we performed additional predictive analysis of  the 141 
genetic risk scores from the SHARE study in PIAMA using more liberal P value thresholds of 142 
1x10-6 and 1x10-4. However, this did not improve genetic risk prediction for asthma ever in 143 
the first 8 years of life with combined familial, perinatal, environmental and GRS AUC values 144 
















Identifying children at high risk for asthma development is important for prevention and 147 
installation of early treatment. However, the GRSs based on SNPs from the largest asthma 148 
GWAS did not improve asthma prediction over familial, perinatal and environmental factors.  149 
Asthma in childhood is a highly heterogeneous disease, with different genes being related to 150 
different sub-types of asthma. The fact that we used a more common asthma definition with 151 
the selection of all children with respiratory symptoms in the first 8 years of life and no 152 
selection on disease specificity, could have influenced our results, although using a more 153 
strict definition (i.e. doctors diagnosed asthma) led to the same conclusion. For the 154 
calculation of the TAGC GRS we therefore added loci specifically related to pediatric asthma. 155 
In addition to this, to improve the prediction of asthma sub-types an even more specific 156 
(subtype-related) selection of SNPs could be beneficial for generating GRSs.  157 
 158 
Asthma has a strong genetic contribution. However, based on the most recent insights in 159 
asthma genetics, genetic variants have no added value in predicting non-specific asthma. 160 
This can be explained in several ways. The known heritability of asthma is due to common 161 
SNPs of modest effect, resulting in many children carrying risk alleles but not having asthma. 162 
Second, although the number of risk SNPs has increased considerably in the past years, 163 
these SNPs still explain only a small fraction of asthma heritability. We also acknowledge 164 
that a substantially larger study may have yielded a significant, but small, increase in AUC 165 
values after inclusion of the genetic risk score. We show in our paper that variation in P value 166 
thresholds for GRS SNP selection made no difference in asthma prediction. This is 167 
underlined by the findings by Zhang et al.9, who propose subsequently to focus more on 168 
effect size distributions than P values for selection of SNPs for disease prediction. These 169 
novel methodological approaches may benefit future genetic risk prediction in asthma. Better 170 
prediction may also depend on our ability to define different sub-types of asthma with shared 171 
etiology. Moreover, better modeling of potential interactions between genes and 172 

















F. Nicole Dijk, MD, PhD,a,b Charlotte Folkersma,a,b Olena Gruzieva, MD, PhD,c,d Ashish 176 
Kumar, PhD,c,e,f Alet H. Wijga, PhD,g Ulrike Gehring, PhD,h Inger Kull, PhD,i,j Dirkje S. 177 
Postma, MD, PhD,k Judith M. Vonk, PhD,b,l Erik Melén, MD, PhD,c,i and Gerard H. 178 
Koppelman, MD, PhDa,b 179 
 180 
Authors affiliations: 181 
aUniversity of Groningen, University Medical Center Groningen, Department of Pediatric 182 
Pulmonology and Pediatric Allergology, Beatrix Children’s Hospital, Groningen, the 183 
Netherlands. 184 
bUniversity of Groningen, University Medical Center Groningen, Groningen Research 185 
Institute for Asthma and COPD (GRIAC), Groningen, the Netherlands. 186 
cInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden  187 
dCentre for Occupational and Environmental Medicine, Stockholm County Council, 188 
Stockholm, Sweden 189 
eDepartment of Public Health Epidemiology, Swiss Tropical and Public Health Institute, 190 
Basel, Switzerland 191 
fUniversity of Basel, Basel, Switzerland. 192 
gDivision of Environmental Epidemiology, Institute for Risk Assessment Sciences, Utrecht 193 
University, Utrecht, The Netherlands 194 
hCenter for Nutrition, Prevention, and Health Services, National Institute for Public Health and 195 
the Environment, Bilthoven, The Netherlands 196 
iSachs’ Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden  197 
jDepartment of Clinical Science and Education, Södersjukhuset and Karolinska Institutet, 198 
Stockholm, Sweden 199 
kUniversity of Groningen, University Medical Center Groningen, Department of Pulmonology, 200 















lUniversity of Groningen, University Medical Center Groningen, Department of Epidemiology, 202 















References  204 
1.  Sears MR. Predicting asthma outcomes. J Allergy Clin Immunol 2015;136:829–36.  205 
2.  Caudri D, Wijga A, A Schipper CM, Hoekstra M, Postma DS, Koppelman GH, et al. 206 
Predicting the long-term prognosis of children with symptoms suggestive of asthma at 207 
preschool age. J Allergy Clin Immunol 2009;124:903–10.  208 
3.  Hafkamp-De Groen E, Lingsma HF, Caudri D, Levie D, Wijga A, Koppelman GH, et al. 209 
Predicting asthma in preschool children with asthma-like symptoms: Validating and 210 
updating the PIAMA risk score. J Allergy Clin Immunol 2013;132:1303-10 211 
4.  Colicino S, Munblit D, Minelli C, Custovic A, Cullinan P. Validation of childhood asthma 212 
predictive tools: A systematic review. Clin Exp Allergy. 2019;doi:10.1111/cea.13336.  213 
5.       Demenais F, Margaritte-Jeannin P, Barnes KC, Cookson WOC, Altmüller J, Ang W, et 214 
al. Multiancestry association study identifies new asthma risk loci that colocalize with 215 
immune-cell enhancer marks. Nat Genet 2018;50:42–50.  216 
6.  Ferreira MA, Vonk JM, Baurecht H, Marenholz I, Tian C, Hoffman JD, et al. Shared 217 
genetic origin of asthma, hay fever and eczema elucidates allergic disease biology. 218 
Nat Genet. 2017;49:1752–7.  219 
7.  Wijga AH, Kerkhof M, Gehring U, de Jongste JC, Postma DS, Aalberse RC, et al. 220 
Cohort profile: the prevention and incidence of asthma and mite allergy (PIAMA) birth 221 
cohort. Int J Epidemiol. 2014;43:527–35.  222 
8.  Kull I, Melen E, Alm J, Hallberg J, Svartengren M, van Hage M, et al. Breast-feeding in 223 
relation to asthma, lung function, and sensitization in young schoolchildren. J Allergy 224 
Clin Immunol. 2010;125:1013–9.  225 
9.   Zhang Y, Qi G, Park JH, Chatterjee N. Estimation of complex effect-size distributions 226 
using summary-level statistics from genome-wide association studies across 32 227 
















Figure Legend 230 
FIG 1. Receiver-operating characteristic graphs of familial, perinatal and environmental risk 231 
score with and without the combination of genetic risk scores in PIAMA and BAMSE. (A-B) 232 
Contains the familial, perinatal and environmental risk score in the PIAMA birth cohort 233 
combined with the genetic risk score (GRS) from the TAGC  consortium (A),and  the GRS 234 
from SHARE consortium (B). (C-D) Contains the familial, perinatal and environmental risk 235 
score in the BAMSE birth cohort combined with the GRS from the TAGC consortium (C), and 236 















TABLE I. General characteristics of the study popul ation and univariate analysis on asthma ever at age  8 years 238 
 239 
 
PIAMA  BAMSE  
Candidate predictor All children (n = 1858) OR (95% CI) P value 
All children 
(n = 427) OR (95% CI) P value 
Familial factors % (n total)       
Parental allergy† 55.5 (1858) 1.87 (1.55-2.26) 6.50x10-11 28.6 (423) 2.74 (1.76-4.28) 8.32 x10-6 
Parental asthma 16.1 (1848) 1.88 (1.47-2.42) 7.35x10-7 26.2 (423) 5.01 (3.04-8.26) 2.52 x10-10 
Parental allergy house dust (mite) 34.0 (1835) 1.77 (1.46-2.15) 9.93x10-9 NA NA NA 
Parental allergy to pets 30.6 (1836) 1.91 (1.56-2.33) 2.83x10-10 37.1 (423) 2.83 (1.87-4.26) 7.36 x10-7 
Parental hay fever 41.8 (1832) 1.51 (1.25-1.82) 1.9x10-5 47.5 (423) 2.41 (1.63-3.56) 0.00001 
Parental inhaled medication 16.2 (1835) 2.20 (1.71-2.83) 9.72x10-10 30.5 (423) 4.65 (2.93-7.39) 7.64 x10-11 
Low parental education‡ 26.7 (1840) 1.25 (1.02-1.54) 0.034 51.1(427) 1.89 (1.28-2.77) 0.001 
Allergic siblings§ 20.5 (1845) 1.52 (1.21-1.90) 3.12x10-4 10.4 (222)  2.45 (0.97-6.21) 0.06 
Asthma siblings 4.6 (1856) 2.88 (1.82-4.58) 7x10-6 6.6 (427) 3.91 (1.55-9.86) 0.004 
Eczema siblings 17.8 (1846) 1.36 (1.07-1.73) 0.012 20.2 (223) 1.02 (0.53-1.97) 0.95 
Hay fever siblings 1.98 (1851) 2.11 (1.04-4.26) 0.038 8.1 (223) 0.97 (0.37-2.55) 0.95 
Perinatal factors % (n total)       
Male gender 51.1 (1858) 1.46 (1.21-1.75) 6.9x10-5 56.2 (427) 2.18 (1.47-3.21) 0.0001 
Low birth weight <2500g 3.1 (1855) 2.20 (1.28-3.78) 0.004 2.4 (424) 4.04 (0.85-19.3) 0.08 
Any breastfeeding 84.4 (1849) 1.07 (0.83-1.37) 0.619 98.3 (424) 3.06 (0.61-15.3) 0.174 
Breastfeeding <16 weeks 63.4 (1849) 1.35 (1.12-1.64) 0.002 18.4 (423) 1.77 (1.07-2.92) 0.03 
Delivery: 
      
   Term (≥37-≤42 weeks) 92.0 (1855) Ref Ref 89.2 (427) Ref Ref 
   Preterm (<37 weeks) 4.7 (1855) 1.55 (1.01-2.39) 0.047 7.0 (427) 2.05 (0.94-4.50) 0.073 
   Postterm (>42 weeks) 3.3 (1855) 1.17 (0.70-1.96) 0.545 3.8 (427) 0.80 (0.29-2.19) 0.662 
Born by caeserian section 8.5 (1841) 1.07 (0.77-1.49) 0.696 16.7 (427) 1.43 (0.85-2.39) 0.174 
Environmental factors % (n total)       
Pets at home during pregnancy 44.4 (1856) 1.22 (1.01-1.47) 0.036 12.7 (427) 0.76 (0.43-1.35) 0.35 















Older siblings living in home 51.7 (1858) 1.18 (0.98-1.41) 0.085 52.2 (424) 1.03 (0.70-150) 0.89 
 240 
OR, Odds ratio; CI, Confidence interval. 241 
* In PIAMA asthma is defined as having one or more of the following three criteria; (1) having ≥1 more attacks of wheeze in the last 12 months, 242 
(2) ≥1 events of shortness of breath (dyspnea) in the last 12 months, (3) prescription of inhalation steroids for respiratory or lung problems 243 
prescribed by a doctor in last 12 months. Since no data on shortness of breath was available in BAMSE we used an adjusted asthma definition 244 
in which asthma was defined as having one or more of the following two criteria; (1) having ≥1 more attacks of wheeze in the last 12 months, (2) 245 
prescription of inhalation steroids for respiratory or lung problems prescribed by a doctor in last 12 months. 246 
† In PIAMA parental allergy is based on parental asthma ever and/or current house dust (mite) allergy and/or pet allergy and/or hay fever. In 247 
BAMSE it is based on mother and/or father with doctor’s diagnosis of asthma and/or doctor’s diagnosis of hay fever in combination with pollen 248 
allergy at baseline. 249 
‡ In PIAMA parental education is defined as an education less than the level of a bachelor’s/master’s degree (HBO/University in Dutch system) 250 
for at least 1 of the parents. In BAMSE it is defined as an education level less than university grade for both of the parents. 251 
§ In PIAMA a sibling with allergy is based on a sibling with asthma ever and/or eczema and/or hay fever. In BAMSE it is based on allergy to 252 
furred animals or pollen. 253 
ǁ In PIAMA smoking during pregnancy is defined as smoking at least the first 4 weeks of pregnancy. In BAMSE it is defined as smoking at least 254 



























Online Repository  1 
 2 
Genetic risk scores do not improve asthma prediction in childhood 3 
 4 
F. Nicole Dijk, Charlotte Folkersma, Olena Gruzieva, Ashish Kumar, Alet H. Wijga, Ulrike 5 















Supplemental Methods 7 
Study populations 8 
PIAMA cohort 9 
The PIAMA study is a multicenter birth cohort, which was initiated in 1996. 7862 women 10 
(2779 with allergy and 5083 without allergy) were invited to participate in the study; 3963 live-11 
born children participated the study (1327 with a mother with allergy were defined as high-12 
risk, and 2726 children with a mother without allergy were defined as low-risk). 13 
Questionnaires for parental completion, partly based on the International Study of Asthma 14 
and Allergies in Childhood core questionnaires, were sent to the parents during pregnancy, 15 
when the children were aged 3 and 12 months, yearly thereafter up to the age of 8 years, at 16 
the age of 11 years, 14 years 16 years, and 17 years. All 1327 high-risk children and a 17 
random sample of 663 low-risk children were selected for an extensive medical examination 18 
at age 4 and 8 years. Blood or a buccal brush was used for DNA extraction during the 19 
extensive medical examination group at age 4 and in all children at age 8. 20 
At age 8 years, 92% of the baseline population was still in the study, and therefore our study 21 
focused on the first 8 years of life. Combined phenotypic and genotype data for this study 22 
was available for 1,968 children.  23 
The study protocol was approved by the Medical Ethical Committees of the participating 24 
university hospitals and all participants gave written, informed consent. A detailed description 25 
of the cohort outline has been published previously.E2 26 
 27 
BAMSE 28 
Between 1994 and 1996, 4,089 newborn infants were recruited in the BAMSE 29 
(Children/Barn, Allergy, Milieu, Stockholm, Epidemiology) study, and questionnaire data on 30 
baseline study characteristics were obtained.E3 The recruitment area included central and 31 
north-western parts of Stockholm. At approximately one, two, four, and eight years of age, 32 
parents completed questionnaires on their children’s symptoms related to asthma and other 33 















At ages 4, and 8 years, blood samples were collected in 2,605 (63.7%), and 2,470 (60.4%) 35 
children, respectively.  36 
DNA was extracted from 2,033 samples at 8 years after exclusion of samples with too little 37 
blood, lack of questionnaire data, or if parental consent to genetic analysis of the sample was 38 
not obtained. From these samples, all children with a doctor’s diagnosis of asthma ever were 39 
selected as cases (n=273) and a random sample of children with no history of asthma or 40 
other allergic diseases was selected as controls (n=273). After Quality Control (QC) a total of 41 
239 cases and 246 controls, all of Caucasian ancestry, were retained for genetic analyses.E4 42 
 43 
Genotyping and imputation  44 
PIAMA cohort 45 
Children from the PIAMA cohort were genotyped on three different platforms. 1377 children 46 
were genotyped with the Illumina Omni Express Exome (OEE) chip, whereas 288 children 47 
were genotyped with the Illumina Omni Express (OE) chip (Illumina Inc, San Diego, CA), 48 
both with the use of an Illumina BeadArray Reader and Iscan at the Genomics Facility of the 49 
University Medical Center Groningen, Groningen, The Netherlands. DNA of 404 children was 50 
genotyped with the Illumina Human610 (HM610) quad array and the use of the Ilumina 51 
Beadarray reader and Iscans at the Centre National de Génotypage (CNG, Evry, France) as 52 
part of the GABRIEL consortium.E5 53 
Quality control inclusion measures per chip on the individuals included a missing genotype 54 
call rate <0.03, IBS <0.1875 and a heterozygosity rate deviating <4SD from the mean. Males 55 
with >1% heterozygote SNPs on chromosome X were excluded. Ethnicity was assessed 56 
using principal component analyses with HapMap CEU, CHB+JPT, and YRI reference 57 
panels, only Caucasians subject were included.E6 58 
QC measures per SNP included missing genotype call rate <0.05, MAF >0.05 and Hardy-59 
Weinberg equilibrium P-value >10-6. SNPs being >1% heterozygous in males on 60 
















Base pair positions of SNPs on the HM610 chip were converted to genome build 37, in 63 
accordance with the OEE chip and the OE chip.  64 
The strand was determined of each SNP and on the different platforms, and if necessary 65 
converted to the positive strand. SNPs with unknown strand orientation were removed. 66 
Discordant genotypes of duplicate SNPs were set to missing. SNPs that showed large 67 
differences in allele frequencies between platforms (>15 %) were either recoded (i.e. alleles 68 
were swapped) in case of an A/T or C/G SNP (and rechecked) or removed in other cases.  69 
Duplicate individuals between the platforms were considered sampling errors and both 70 
individuals were removed.  71 
The single chips were matched to the 1000G reference set with respect to basepair positions 72 
Resemblance between the chip and the 1000G European panel (EUR) of rs-numbers, 73 
alleles, and allele frequencies of SNPs on the autosomal chromosomes were checked and if 74 
discrepant deleted.  75 
 76 
After quality control, a total of 1968 individuals remained, with the presence of 873 (44,4%) 77 
high-risk children, Imputation was performed per platform using IMPUTE 2.0.E7 against the 78 
reference data set of the ALL panel of 1000G (version 3, March 2012).E8 After imputation, 79 
only SNPs of high quality (info-score IMPUTE ≥ 0.7) were selected per chip. We removed 80 
SNPs that showed discrepancy between chips in allele frequency (> 15 %) (N=1795). 81 
Rs-numbers and insertions or deletions were separately merged using GTOOL 82 
(http://www.well.ox.ac.uk/~cfreeman/software/gwas/gtool.html) due to potential localization at 83 
the same base-pair position. The obtained files were combined into one dataset (SNPs 84 
N=11,713,219) that was used for further analyses.  85 
 86 
BAMSE 87 
Genotyping was done on the Illumina Human610 Quad platform at the Centre National de 88 















For imputation, the genotyped SNPs were filtered at - call rate >95%, Hardy Weinberg P-90 
value > 1x10-6 and MAF > 0.01; and sample call rate > 95%; and 515,445 SNPs remained 91 
after quality control. These were imputed using MiniMac release stamp 2012-11-16 and the 92 
GIANT ALL reference panel, phase 1 v3.20101123 onto N=30,061,897 variants. The 93 
resultant SNPs were filtered for imputation quality threshold at Rsq >=0.3. 94 
 95 
Outcome variable 96 
PIAMA 97 
The primary outcome variable of this study is based on asthma ever at age 8 years, in which 98 
asthma is defined by the following characteristics: one or more attacks of wheeze in the last 99 
12 months, or one or more events of shortness of breath (dyspnea) in the last 12 months, or 100 
prescription of inhaled corticosteroids for respiratory or lung problems prescribed by a doctor 101 
in the last 12 months. A child who had one or more of these characteristics was categorized 102 
as having ‘asthma’. A child who had none of these characteristics was categorized as ‘not 103 
having asthma’. At 1 and 2 years of age, data on shortness of breath is not available and the 104 
data on steroids use is limited. Therefore our outcome variable is based on asthma ever from 105 
age 3 till age 8 years.  106 
We acknowledge that with our asthma ever definition we select all children with respiratory 107 
symptoms in the first 8 years of live and that some included children will not develop asthma 108 
but have respiratory symptoms. Therefore we performed our analyses as well on a the 109 
PIAMA variable doctors diagnosis of asthma at age 8, which is defined as asthma diagnosed 110 
ever by a doctor and asthma in the last 12 months at the age of 8 years.  111 
 112 
BAMSE 113 
In BAMSE no data were available on one or more events of shortness of breath (dyspnea) in 114 
the last 12 months. Therefore, we used an adjusted diagnosis of asthma ever at age 8 year 115 
based on: (1) one or more attacks of wheeze in the last 12 months, (2) prescription of inhaled 116 















A child who had at least one of these characteristics was categorized as having ‘asthma’. A 118 
child who had none of these characteristics was categorized as ‘not having asthma’. 119 
 120 
Familial, perinatal and environmental variables 121 
PIAMA 122 
In the PIAMA cohort a prediction model for asthma at age 8 years in preschool children who 123 
have asthma-like symptoms was previously published.E9,E10 We used these data, in 124 
combination with other asthma associated studies performed in PIAMA, to select candidate 125 
predictor variables present at birth.E9-E11 We took into account that for a prediction model the 126 
variables have to be available in the first months of life and not involve invasive tests. We 127 
divided the candidate predictors in three groups; (1) familial, (2) perinatal and (3) 128 
environmental factors. If the candidate predictors were not present in our dataset we 129 
searched for a surrogate or combined marker. 130 
 131 
BAMSE 132 
In the BAMSE cohort, predictor variables were defined in accordance or as similar as 133 
possible with PIAMA definitions (as described above) using the data collected via parental 134 
questionnaires as well as Medical Birth Registry. 135 
 136 
Reference datasets and SNP selection 137 
TAGC/SHARE consortia 138 
We used the findings from the two largest asthma and allergy genetics consortia to 139 
summarize different single nucleotide polymorphisms (SNPs) associated with asthma. The 140 
first study is the Trans-National Asthma Genetic Consortium (TAGC)E12 in which the largest 141 
meta-analysis of asthma GWAS (23,948 cases, 118,538 controls) was conducted from multi-142 
ancestry populations. New asthma loci were identified and associations at known asthma loci 143 















were associated with pediatric asthma. Of those selected SNPs, 1 was missing leaving 22 145 
SNPS to be used for further analyses.  146 
The second study is the SHARE ConsortiumE13, a large study about the three most common 147 
atopic diseases, asthma, hay fever (allergic rhinitis) and eczema (atopic dermatitis). A GWAS 148 
(360,838 samples) was performed on an allergic disease phenotype. Because these 149 
diseases frequently occur in the same individuals and partly have a shared genetic origin, 150 
they identified individual genetic risk variants shared between asthma, hay fever and 151 
eczema. They also identified 6 variants that had stronger effect in one allergic disease, which 152 
confirmed that the majority acted as shared risk factors. The main association result showed 153 
136 SNPs independently associated with risk of allergic disease, of which 133 were present 154 
in PIAMA and used for this study. 155 
We performed additional sensitivity analyses using results of the SHARE consortium dataset 156 
to investigate if including SNPs that were less significantly associated would improve asthma 157 
prediction. To this aim, we downloaded the results from the SHARE consortium; and applied 158 
two less stringent significance cut-offs: 1x10-6 and 1x10-4. Results of one of the largest 159 
cohorts, 23andme, were not included in this download and therefor these results differ 160 
slightly from the main results of the SHARE-analysis. 161 
To select independently associated SNPs based on the selected p-value thresholds we used 162 
Genome Wide Complex Trait (GCTA) software (https://cnsgenomics.com/software/gcta/). We 163 
used data from the LifeLines cohort study as a reference set.E14 LifeLines is a large Dutch 164 
population-based cohort study and biobank that was established as a resource for research 165 
on complex interactions between environmental, phenotypic and genomic factors in the 166 
development of chronic diseases and healthy ageing. Genomic imputed data, based on the 167 
1000G reference set, are available of 13,386 participants. With the use of the --cojo-slct 168 
option independent SNPs were selected using the default settings of the program (i.e. –cojo-169 
wind 10000 and --cojo-collinear=0.9). Weighted GRSs were calculated in the same manner 170 
as for the TAGC and SHARE GRS already stated in the paper. This  resulted in a SNP set of 171 















Statistical analysis 173 
Predictive modeling of familial, personal and environmental factors. 174 
We performed univariate logistic regression to assess the predictive value of the candidate 175 
predictors on asthma. We selected predictors of each category (familial factors, perinatal 176 
factors, environmental factors) which were used in the previous asthma prediction model for 177 
children with symptoms in the PIAMA birth cohortE9,E10 and had a P-value <0.10 in our 178 
univariate analysis. All these variables were entered in a multivariate logistic regression 179 
model. Using a stepwise backward regression strategy we selected our final predictor 180 
models (one model per category) addressing the change in P values and Cox-Snell and 181 
Nagelkerke R-square (closest to 1) to select the best model.  182 
 183 
Familial, perinatal and environmental risk score 184 
To develop these risk scores we created a weighted score per category using the regression 185 
coefficients from the final multivariate models to determine the score for each variable. In the 186 
weighted score per category the scores were calculated and rescored in a range from 0-10 187 
giving equal weight to each category. With this score the variables were tested in a total 188 
model instead of the separate categories (familial, perinatal and environmental factors). The 189 
weight for each variable was calculated by using the regression coefficients from the model 190 
including all predictor variables.  191 
Association analyses with asthma ever at age 8 years were performed per familial, perinatal 192 
and environmental risk score (see table 1 and E1 for selected variables).  193 
 194 
Genetic risk score 195 
We generated weighted genetic risk scores (GRSs) based on significant SNPs selected from 196 
the previously published TAGC (P < 5x10-8) and SHARE (P < 3x10-8) studies and used the 197 
reported ORs of the meta-analysis for weighing the GRSs.E12,E13 The GRSs were calculated 198 
with the use of SPSS for Windows, Version 24.0 (IBM SPSS Statistics). The dosages of the 199 















To construct a weighted GRS we took into account the effect sizes of the SNPs. For 201 
developing the weighted score we used the odds ratios and multiplied them with the dosages 202 
of the risk alleles, summed them up and then divided the results by two times the sum of the 203 
weights. 204 
To calculate the TAGC and SHARE GRS in BAMSE, data was available for 19 of the 23 and 205 
133 of the 136 SNPs, respectively. For the additional sensitivity analysis in SHARE using 206 
less stringent significant thresholds, data was available for 172 and 613 SNPs, respectively. 207 
Association analyses with asthma ever at age 8 years were performed per genetic risk score 208 
(threshold: TAGC; P < 5x10-8 and SHARE; P < 3x10-8). 209 
  210 
Combination of risk scores 211 
We combined the familial, perinatal and environmental risk scores with the GRSs to 212 
construct two final models; (1) the familial, perinatal and environmental risk scores with the 213 
TAGC GRS, and (2) the familial, perinatal and environmental risk scores with the SHARE 214 
GRS. To determine the discriminative ability we conducted a receiver-operating 215 
characteristic (ROC) curve. ROC-curves of the risk models were made using the predicted 216 
probabilities from the logistic regression models for the asthma ever at age 8 years definition. 217 
The area under the ROC-curve (AUC) was calculated. The AUC ranges from 0 to 1, in which 218 
a value of 0.5 means not better than chance, and a value closer to 1 means a better 219 
discrimination.E15 Significant differences between the AUCs were tested.E16 The predicted 220 
probabilities of the final models were categorized into deciles. For each decile of predicted 221 
asthma risk the mean of the 4 included risk scores were plotted.  222 
 223 
Validation of the model 224 
Optimism caused by overfitting was investigated by internal validation of the familial, 225 
perinatal and environmental weighted risk scores in PIAMA with the use of the bootstrapping 226 

















Supplemental Results 230 
General characteristics and univariate analysis 231 
General characteristics of the study population and univariate analysis on asthma ever at 232 
age 8 years in PIAMA and BAMSE are shown in Table 1.  233 
Of the 1,968 children with genotype data in the PIAMA cohort, 1,858 children had information 234 
on the presence of asthma in the first 8 years of life. Data on doctor’s diagnoses at age 8 235 
was available for 1,794 children. In BAMSE, 427 of the 485 children with genetic data had 236 
information on the presence of asthma ever at age 8 year and were selected for this study.  237 
In the PIAMA study population with data on asthma ever at age 8 years the percentage of 238 
high risk children (defined as children of allergic mothers) was 36.9% as compared to 31.2% 239 
in the PIAMA population as a whole and 29% in the general population of pregnant women 240 
from which PIAMA participants were recruited.  241 
The prevalence of children with allergic parents is 55.5% in PIAMA, compared to 28.6% in 242 
BAMSE. However, the number of children with asthma ever at age 8 were comparable 243 
between the cohorts, with 42.6% (N=792) cases in PIAMA and 50.4% (N=215) cases present 244 
in BAMSE. In PIAMA 4.0% (N=71) children had doctors diagnosis at age 8.  245 
 246 
Multivariate analysis and calculation of familial, perinatal and environmental risk scores 247 
Variables that were found to have a significant association with the risk of asthma 248 
development were further tested in the multivariable analysis. Despite being significantly 249 
associated with asthma in the univariate analysis, parental allergy to house dust (mite) (P = 250 
0.7) was not significantly associated in the multivariate analysis, nor was there a significant 251 
association between asthma and having siblings with eczema (P = 0.2) or hay fever (P = 252 
0.6). The final model of familial risk score contained the variables parental allergy, parents 253 
allergic to pets, low parental education, parental inhaled medication to improve breathing, 254 
and siblings with asthma. Regarding the perinatal factors, both preterm (P = 0.6) and post-255 















from the model. Male gender, low birth weight <2500 g, and breastfeeding <16 weeks were 257 
the final variables for the perinatal risk score. Selected variables for the environmental risk 258 
score were pets at home during pregnancy, smoking mother during pregnancy, and older 259 
siblings living at home. A risk score was calculated by using the regression coefficient of 260 
each predictor variable shown in Table 1. A weighted risk score per category was developed 261 
by assigning points for each variable based on the regression coefficient with a range from 0 262 
to 10. Scores per category are shown in Table E1. 263 
 264 
Combined risk scores 265 
Calibration of our models showed that the mean familial risk score increased most per decile, 266 
in contrast to the almost horizontal lines of the GRSs from TAGC and SHARE (Fig E1A-B). 267 
The increases per decile of the predicted probability of the perinatal and environmental 268 
scores were both slightly lower than the family score. 269 
 270 
Internal validation of the model  271 
The optimism corrected C-statistic (i.e. AUC) of the familial, perinatal and environmental 272 
weighted risk score in PIAMA showed a value of 0.65 (uncorrected AUC=0.65).  273 
Replication results 274 
ROC-curves of the two risk models in BAMSE; (1) the familial, perinatal and environmental 275 
risk scores with the TAGC GRS, and (2) the familial, perinatal and environmental risk scores 276 
with the SHARE GRS are shown in Fig 1C-D.  277 
Fig E2A-B shows the observed mean score of the predicted probability for each decile. The 278 
horizontal lines of the TAGC and SHARE based GRSs indicate a low ability to predict 279 
asthma. Familial and perinatal scores show better prediction when compared to the genetic 280 
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Supplementary Figure Legends 329 
FIG E1. Mean predicted scores per decile for each score in the PIAMA cohort. (A-B) 330 
Contains the familial, perinatal and environmental risk score in the PIAMA birth cohort 331 
combined with the genetic risk score (GRS) from the TAGC consortium (A), and the GRS 332 
from SHARE consortium (B). Scores are all based on asthma ever at age 8 years, in which 333 
asthma is defined as having one or more of the following three criteria; (1) having ≥1 more 334 
attacks of wheeze in the last 12 months, (2) ≥1 events of shortness of breath (dyspnea) in 335 
the last 12 months, (3) prescription of inhalation steroids for respiratory or lung problems 336 
prescribed by a doctor in last 12 months. 337 
 338 
FIG E2. Mean predicted scores per decile for each score in the BAMSE cohort. (A-B) 339 
Contains the familial, perinatal and environmental risk score in the BAMSE birth cohort 340 
combined with the genetic risk score (GRS) from the TAGC consortium (A), and the GRS 341 
from SHARE consortium (B). Scores are all based on asthma ever at age 8 years, in which 342 
asthma is defined as having one or more of the following two criteria; (1) having ≥1 more 343 
attacks of wheeze in the last 12 months, (2) prescription of inhalation steroids for respiratory 344 















Supplemental Tables 346 
TABLE E1. Familial, perinatal and environmental weighted risk scores from 0 to 10 in PIAMA. 347 
Predictor Beta OR (95% CI) P value Score 
Familial risk score         
Parental allergy* 0.32 1.38 (1.08-1.76) 0.01 1.5 
Parents allergic to pets 0.36 1.43 (1.10-1.85) 0.007 1.5 
Parental inhaled medication 0.43 1.54 (1.17-2.04) 0.002 2 
Siblings with asthma 0.90 2.46 (1.52-3.99) 2.55x10-4 4 
Low parental education† 0.29 1.33 (1.07-1.65) 0.01 1 
 348 
Predictor Beta OR (95% CI) P value Score 
Perinatal risk score        
Male gender 0.37 1.44 (1.20-1.74) 1.16x10-4 3 
Breastfeeding <16 weeks 0.28 1.32 (1.09-1.60) 0.005 2 
Low birth weight <2500 g 0.76 2.15 (1.24-3.70) 0.006 5 
 349 
Predictor Beta OR (95% CI) P value Score 
Environmental risk score         
Pets at home during pregnancy 0.19 1.21 (1.00-1.46) 0.05 2.5 
Smoking mother during 
pregnancy‡ 0.37 1.45 (1.13-1.88) 0.004 5 
Older siblings living at home 0.18 1.20 (1.00-1.45) 0.05 2.5 
AUC of combined risk scores   0.65     
 350 
OR, Odds ratio; CI, Confidence Interval; AUC, Area Under the Curve 351 















* Parental allergy is defined as parental asthma ever and/or current house dust (mite) allergy and/or pet allergy and/or hay fever’ 353 
† Parental education is defined as an education less than the level of a bachelor’s/master’s degree (HBO/University in Dutch system) for at 354 
least 1 of the parents. 355 















TABLE E2. Results of association with asthma ever at age 8 years per familial, perinatal, environmental and genetic weighted risk 357 
scores in PIAMA and BAMSE.  358 
  PIAMA BAMSE 
 Risk score OR (95% CI) P value OR (95% CI) P value 
Familial risk score 1.25 (1.19 - 1.32) 3.17x10-19 1.46 (1.32 - 1.63) 8.45x10-13 
Perinatal risk score 1.14 (1.09 - 1.20) 2.60x10-8 1.27 (1.14 - 1.42) 1.00x10-5 
Environmental risk score 1.08 (1.04 - 1.12) 5.30x10-5 1.06 (0.98 - 1.15) 0.14 
TAGC GRS (threshold P<5x10-8) 1.23 (1.10 - 1.38) 4.32x10-4 1.52 (1.19-1.96) 0.01 
SHARE GRS (threshold P<3x10-8) 1.72 (1.21 - 2.44) 0.003 4.75 (2.25-10.01) 4.20x10-5 
 359 
OR, Odds ratio; CI, Confidence Interval; GRS, Genetic risk score 360 
Asthma is defined as having one or more of the following three criteria; (1) having ≥1 more attacks of wheeze in the last 12 months, (2) ≥1 361 
events of shortness of breath (dyspnea) in the last 12 months, (3) prescription of inhalation steroids for respiratory or lung problems prescribed 362 
by a doctor in last 12 months. In BAMSE we used an adjusted asthma definition in which asthma was defined as having one or more of the 363 
following two criteria; (1) having ≥1 more attacks of wheeze in the last 12 months, (2) prescription of inhalation steroids for respiratory or lung 364 
problems prescribed by a doctor in last 12 months. 365 
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